Physician profile
Jung Yoon
NPI 1669902318
$10,417.71
in general payments reported to CMS, 2019-2025
31 companies · $3,149 in 2025
The $3,149 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.01 · 2020: $640 · 2021: $1,053 · 2022: $995 · 2023: $2,241 · 2024: $2,305 · 2025: $3,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,527 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,526.73 |
| Education | $167.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,947.45 | 2020-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,927.37 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,711.92 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $795.86 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $629.86 | 2022-2025 | |
| Glaxosmithkline, LLC. | $457.60 | 2020-2025 | Benlysta, Nucala |
| Ani Pharmaceuticals, INC. | $409.33 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Mallinckrodt Hospital Products INC. | $370.20 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $264.55 | 2022-2023 | Krystexxa |
| Sobi, INC | $247.27 | 2019-2025 | |
| Lilly USA, LLC | $240.98 | 2020-2024 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $192.79 | 2020-2025 | Orencia |
| Pfizer INC. | $185.30 | 2021-2023 | |
| Genentech USA, INC. | $161.87 | 2020-2025 | Actemra |
| Genzyme Corporation | $135.49 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.80 | 2022-2025 | Spevigo, Ofev |
| Radius Health, INC. | $90.64 | 2022-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $83.67 | 2024-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $80.61 | 2025 | Strensiq |
| Sandoz INC. | $79.38 | 2024-2025 | Hyrimoz |
| Astrazeneca Pharmaceuticals LP | $63.98 | 2022-2025 | Saphnelo |
| Sanofi-Aventis U.S. LLC | $55.00 | 2021 | |
| Globus Medical, INC. | $26.90 | 2025 | Senza |
| Organon LLC | $23.66 | 2025 | Renflexis, Hadlima |
| Tersera Therapeutics LLC | $23.19 | 2025 | Quzyttir |
| Invivyd INC | $21.05 | 2025 | Pemgarda |
| Edwards Lifesciences Corporation | $19.26 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.83 | 2023 | Quviviq |
| Kiniksa Pharmaceuticals, LTD. | $18.47 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $15.70 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $7.73 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jung Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.